PressApril 4, 2023 Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
PressApril 4, 2023 First Avenue Ventures Life Science Fund I Invests in Diamond Therapeutics to Accelerate Innovation in Mental Health
PressApril 4, 2023 Psyence Group Announces Closing of Fourth Tranche of Private Placement and Conversion of Convertible Debt Note
PressApril 3, 2023 Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
PressApril 3, 2023 Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
PressApril 3, 2023 Mindset Pharma to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
PressApril 3, 2023 Filament Health Reports Q4 and Year End 2022 Financial Results and Operational Highlights
PressApril 3, 2023 Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial
PressMarch 31, 2023 Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial
PressMarch 31, 2023 BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
PressMarch 31, 2023 PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
PressMarch 31, 2023 NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression
PressMarch 29, 2023 PSYC’s CEO to Moderate Panel at Film Screening for ESPN’s Upcoming Documentary, “Peace of Mind”
PressMarch 29, 2023 Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics
PressMarch 29, 2023 Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
PressMarch 27, 2023 Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting
PressMarch 27, 2023 Numinus Launches the Practitioner Certification Pathway – a Complete Psychedelic-Assisted Therapy Training Program
PressMarch 24, 2023 FSD Pharma Inc. Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial
